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Regulation of protein synthesis at the level of translation initiation is fundamentally important for the control of cell
proliferation under normal physiological conditions. Conversely, misregulation of protein synthesis is emerging as a major
contributory factor in cancer development. Most bulk protein synthesis is initiated via recognition of the mRNA 5' cap and
subsequent recognition of the initiator AUG codon by a directional scanning mechanism. However, several key regulators of
tumour development are translated by a cap-independent pathway. Here we review eukaryotic translation initiation, its
regulation and the ways in which this regulation can break down during tumorigenesis.
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TRANSLATION RATES AND GROWTH CONTROL
Cell growth and proliferation rates depend critically upon the rate
of protein synthesis. Normal cells that are able to proliferate gener-
ally do so transiently in response to appropriate extracellular cues.
Withdrawal of these growth stimuli leads to cell cycle exit asso-
ciated with a marked decrease in protein synthesis. In
mammalian ﬁbroblasts, inhibiting overall protein translation by
50% is sufﬁcient to prevent the onset of DNA replication following
mitogenic stimulation. Consequently there exists a critical thresh-
old level of total protein synthesis, which must be exceeded in
order to commit each cell to a round of replication. This has been
interpreted as a requirement to accumulate one or more unstable
protein(s) to a predetermined level. The G1 cyclins have emerged
as prime candidates for this class of regulatory proteins (reviewed
in Zetterberg et al, 1995).
The rate of synthesis of any given protein is determined primar-
ily by the level of translation initiation. In mammalian cells, this is
a complex process that requires collaboration between multiple
eukaryotic initiation factors (eIFs: reviewed in Pestova et al,
2001). In brief, a ternary complex is formed between eIF2, GTP
and the initiator methionyl-tRNA (met-tRNAi), while free 40S
ribosomal subunits are bound to eIF3, a large, multi-subunit,
initiation factor. Free 60S ribosomal units are similarly bound to
the monomeric eIF6. Together, eIF3 and eIF6 prevent premature
association of the 60S and 40S ribosomal subunits. The ternary
complex is transferred to eIF3/40S along with eIF1 and eIF1A, to
form a 43S pre-initiation complex. eIF3 can now bind to the eIF4F
complex, which is associated with the mRNA, thus linking the 40S
ribosome to the mRNA and generating the 48S pre-initiation
complex (Figure 1).
eIF4F itself consists of three components: eIF4G, eIF4E, and eIF4A.
eIF4G binds eIF3 and acts as a scaffold for eIF4E and eIF4A. eIF4E
recognises and binds the 5' mRNA cap structure while the RNA-
dependent ATPase eIF4A is thought to unwind secondary structure
in the 5' untranslated region (UTR). eIF4B is an additional factor that
may stimulate the eIF4A helicase activity and promote RNA binding.
The poly(A) tail of the mRNA interacts with poly(A) binding protein
(PABP), which in turn has a binding site on eIF4G allowing the
mRNA to circularise. The 48S pre-initiation complex now scans
downstream from the mRNA 5' end until it encounters an AUG
initiation codon. This process can only occur if the 43S complex
has formed in the presence of eIF1 and eIF1A.
With the Met-tRNAi positioned at the AUG codon, eIF5 inter-
acts with the pre-initiation complex via EIF2 and eIF3. eIF2-bound
GTP is hydrolysed and eIF2-GDP is released. The hydrolysis of a
second GTP bound to the initiation factor eIF5B is activated by
the 60S ribosomal subunit. These two successive GTP hydrolysis
events, and the simultaneous release of eIF3, are essential for the
joining of the 60S subunit. A functional 80S ribosome is conse-
quently formed and peptidyl transfer can now occur.
REGULATION OF TRANSLATION
Mammalian translational initiation control is focused on two key
steps, the formation of the ternary complex and binding of the
40S-ribosome to the 5' mRNA cap structure.
Regulation of ternary complex formation
The protein kinases PKR, HRI and PERK can phosphorylate serine
51 of the a subunit of eIF2 and this results in an increased afﬁnity
for eIF2B, a guanine nucleotide exchange factor. Normally, eIF2B
catalyses the exchange of eIF2-bound GDP with GTP so that a
new interaction with met-tRNAi can take place and the ternary
complex can re-form. Phosphorylated eIF2a sequesters eIF2B,
preventing the formation of additional ternary complexes and inhi-
biting translation initiation (Sood et al, 2000). eIF2a has also been
shown to be cleaved during apoptotic cell death, rendering eIF2
inactive and consequently disabling the ternary complex (Marissen
et al, 2000).
Regulation of mRNA-binding
mRNA binding to ribosomes is generally the rate limiting step in
translation initiation and consequently is a major focus for regula- Received 14 January 2002; accepted 8 February 2002
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between the capped mRNA and the ribosomes and drastically inhi-
bits translation. This disruption can be a result of eIF4G cleavage
(e.g. by caspase 3, in response to apoptotic signals) or sequestration
into insoluble bodies (e.g. Hsp27 binding after heat shock; Cuesta
et al, 2000; Holcik et al, 2000). Formation of eIF4F complexes also
depends upon the presence of active eIF4E which, while it is the
least abundant of the translation initiation factors, is essential for
binding the pre-initiation complex to the cap structure.
Availability of eIF4E is regulated through the activities of two 4E
binding proteins, 4E-BP1 and 4E-BP2. These exist in a hypophos-
phorylated state in quiescent cells and have the capacity to seques-
ter eIF4E by competing with eIF4G for a common 4E-binding site.
This in turn prevents assembly of the eIF4F complex and inhibits
translation initiation. 4E-BP1 hyperphosphorylation at multiple
amino acid residues occurs in response to growth factors such as
insulin, IGF-1 and angiotensin-II and involves protein kinases
including FRAP, MAP kinases, PKC, ATM and casein kinase II
(reviewed by Gingras et al, 1999). Hyperphosphorylated 4E-BP1
dissociates from eIF4E, leaving it free to participate in eIF4F
formation. Conversely, in heat shocked or mitotic cells, depho-
sphorylation of 4E-BP1 correlates with decreased cap-dependent
translation.
The activity of eIF4E may be regulated by phosphorylation (e.g.
by the MAP kinase-stimulated protein kinase, Mnk1). Low levels of
eIF4E phosphorylation are correlated with reduced translation rates
in quiescent and mitotic cells. However, there is not a universal
relationship between eIF4E phosphorylation and increased transla-
tion (Gingras et al, 1999).
CAP-INDEPENDENT TRANSLATION
In addition to the cap-dependent mechanism described above, a
subset of cellular mRNAs can utilise an alternative mode of transla-
tion initiation known as internal ribosomal entry. The small
ribosomal subunit can bind within the mRNA at speciﬁc internal
ribosome entry sites (IRES), which then direct translation initiation
from a downstream AUG. Internal ribosome entry bypasses the
requirement for 5' cap binding and consequently allows translation
of speciﬁc transcripts when global protein synthesis has been inhib-
ited, for example during mitosis or in response to stress. A number
of cellular mRNAs containing IRES elements encode factors that
can inﬂuence proliferation (Table 1). These include XIAP, an inhi-
bitor of apoptosis, as well as the pro-apoptotic Apaf-1 and c-Myc.
The latter can drive both cell proliferation and apoptosis and its
expression is deregulated in a number of human malignancies.
The angiogenic factors VEGF and FGF-2 also have transcripts
containing IRES elements and promote endothelial cell growth
following hypoxic stress (Holcik et al, 2000). These factors and
their receptors are strongly implicated in cancer, with high levels
linked to tumour progression, metastasis and poor prognosis.
EUKARYOTIC TRANSLATION INITIATION FACTORS
AND CANCER
A variety of lines of evidence have contributed to the emerging
view that abnormal regulation of translation initiation is a wide-
spread, and perhaps even universal, feature of tumour
development.
eIF2
Elevated expression of eIF2a has been reported in transformed cell
lines. Furthermore, overexpression of eIF2a (or a mutant form
which cannot be phosphorylated on serine 51) is sufﬁcient to cause
malignant transformation. Constitutively increased expression of
eIF2a (together with eIF4E) is observed in non-Hodgkins lympho-
mas when compared with normal B-cells and correlates with
disease aggression. eIF2a levels are also signiﬁcantly higher in
stomach, colon and rectal tumours than in normal gastrointestinal
tissue (Wang et al, 1999; Lobo et al, 2000).
Down-regulation of eIF2a kinases could be comparable to the
effect of up-regulating eIF2a, and reduced levels of HRI have been
reported in epithelial ovarian cancers (Hwang et al, 2000). Conver-
sely, PKR has been described as both a tumour suppressor and a
growth promoter. PKR, however, is involved in various, alternative
signaling pathways and has diverse roles (Jagus et al, 1999).
eIF3
eIF3 is the largest of the eukaryotic initiation factors and comprises
11 non-identical sub-units of which ﬁve have so far been impli-
cated in human cancer. eIF3a (p150, also known as p170) is the
largest eIF3 subunit and is overexpressed in a variety of tumours
when compared with normal control tissues. These include cancers
of the breast, cervix, esophagus and lung (Lin et al, 2001; Pincheira
et al, 2001). eIF3b (p116) has also been found signiﬁcantly up-
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Figure 1 Components of the 48S translation pre-initiation complex. A
polyadenylated mRNA (top) is circularised by being bound at its 5' cap
by eIF4E and at its 3' end by poly(A)-binding protein (PABP). Both of these
proteins are in turn bound to the scaffold protein eIF4G, which also pro-
vides a link to the 40S ribosomal subunit (bottom). For additional details
see text.
Table 1 Examples of cellular mRNAs with IRES elements (adapted from
Holcik et al, 2000)
Gene product Function
FGF-2 Angiogenesis (heat shock, oxidative stress)
VEGF Angiogenesis (hypoxia)
PDGF Growth/differentiation
IGF-II Growth/survival
ODC Polyamine biosynthesis
PITSLRE Cell cycle?
c-Myc Cell proliferation and apoptosis
XIAP Apoptosis inhibitor
Apaf-1 Pro-apoptotic
DAP5/NAT1/p97 Apoptosis
eIF4G Translation initiation
BiP Chaperone
NRF Transcription factor
AML1/RUNX1 Transcription factor
Mnt
Cat-1 Amino acid transporter
Kv1.4 Potassium channel
MYT2 DNA binding protein
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transcript levels of eIF3c (p110) were observed in all testicular
seminomas examined in a recent study (Rothe et al, 2000). In a
screen for ampliﬁed genes in breast and prostate cancer, eIF3h
(p40) mRNA levels were found to be up-regulated in approxi-
mately 30% of prostate tumours and 20% of breast carcinomas
(Nupponen et al, 1999).
Presumably, increases in expression of eIF3 subunits could lead
to an increase in the amount of total eIF3, though additional biolo-
gical roles for individual subunits independent of the eIF3 complex
cannot be ruled out. Although eIF4E is rate limiting for cap-depen-
dent protein synthesis, eIF3 has been reported to bind directly to
the IRESs of hepatitis C virus (HCV) and classical swine fever virus
(CSFV; Sizova et al, 1998). eIF3 may therefore have an important
role in cap-independent translation of certain cellular mRNAs,
which could confer a growth advantage.
Interestingly, the levels of eIF3e (p48) mRNA were recently
found to be signiﬁcantly reduced in approximately 40% of
mammary carcinomas and 30% of non-small cell lung cancers.
Murine eIF3e is encoded by Int-6, which was identiﬁed as site of
mouse mammary tumour virus (MMTV) integration in mammary
tumours. Consequently, disruption of this gene has been implicated
in tumorigenesis (Marchetti et al, 2001). It has also been postulated
that eIF3e/INT6 may be a negative regulator of eIF3. The subunit
can interact with the interferon-inducible protein, p56 and inhibit
protein synthesis in vitro and in vivo (Guo et al, 2000). Reduced
levels of eIF3e may therefore serve to increase eIF3 activity and
hence the potential for transformation.
eIF4G
eIF4G is a large ‘scaffolding’ protein which interacts with eIF3,
eIF4E, eIF4A, PABP, Mnk1, 40S ribosome and mRNA. Two related
eIF4G proteins (eIF4GI and eIF4GII) exist in mammalian cells but
both form eIF4F complexes capable of protein synthesis. DAP5/
NAT1/p97 is a third eIF4G-like protein, strongly related to the
C-terminal two thirds of eIF4G but entirely lacking the N-terminal
third. Consequently it can bind eIF3 and eIF4A but not eIF4E.
DAP5 is a ‘death associated protein’ and was originally isolated
as a mediator of apoptotic cell death (reviewed by Gingras et al,
1999). However, in a recent study, over-expression of DAP5
protected neuroblastoma cells from IFNg-induced apoptosis
(Wittke et al, 2001). Over-expression of eIF4GI causes malignant
transformation in NIH3T3 cells and increases both cap-dependent
and cap-independent translation in FM3A cells (Hayashi et al,
2000). eIF4GI could mediate these effects by competing with 4E-
BPs for binding of eIF4E and preventing inhibition of cap-depen-
dent protein synthesis. Excess eIF4G could also bind directly to
cellular IRES elements and increase translation of the growth
factors and anti-apoptotic proteins discussed above. High levels
of DAP5 could similarly promote cap-independent translation. In
addition eIF4G mRNA itself contains an IRES, which in principle
could perpetuate its own over-expression. However, increased
expression of eIF4G does not appear to be common in human
tumours, although ampliﬁcation of the eIF4G gene has been
reported in approximately 30% of squamous cell lung carcinomas
(Brass et al, 1997).
eIF4A
Like eIF4G, two active isoforms of eIF4A exist in mammalian cells
(eIF4AI and eIF4AII) and these appear to be functionally inter-
changeable. Human eIF4AII is closely related to eIF4AI but their
expression differs in developmental regulation and tissue speciﬁcity
(Gingras et al, 1999). Upregulation of eIF4AI has been observed in
primary hepatocellular carcinomas, where it correlated with a high-
er histological grading (Shuda et al, 2000), and in melanoma cell
lines compared to normal melanocytes (Eberle et al, 1997).
eIF4E
Of all the eIFs, eIF4E is the most strongly implicated in malig-
nancy. Increased eIF4E mRNA or protein levels have been
reported in carcinomas of the bladder, head and neck, liver, colon
and breast (Shuda et al, 2000; Berkel et al, 2001). This is thought to
reﬂect a primary role for eIF4E in tumorigenesis, since enforced
over-expression of eIF4E in vitro causes malignant transformation
and deregulated cell growth. Over-expression of 4E-BPI in eIF4E-
transformed cells can partially reverse their tumorigenicity. Simi-
larly, transformed rat ﬁbroblasts expressing an antisense eIF4E
mRNA are less tumorigenic when injected into mice (Gingras et
al, 1999). Src-transformed cell lines show increased eIF4E phos-
phorylation (potentially enhancing the activity of the protein) as
well as increased phosphorylation of 4E-BPI (Frederickson et al,
1991; Tuhackova et al, 1999).
Over-expression of eIF4E could accentuate translation of
mRNAs containing long 5' UTRs with complex secondary struc-
ture. Since eIF4E is rate limiting, various classes of mRNAs
compete with each other for translation initiation, establishing an
order of priority. Transcripts with unstructured 5' UTRs are more
easily bound and scanned by the pre-initiation complex and hence
are preferentially translated. Transcripts with highly structured 5'
UTRs are less efﬁciently translated by the cap-dependent pathway
and rely more on the eIF4A helicase to unwind the 5' UTR
RNA. Sequence analyses of vertebrate cDNAs have shown that
those with complex 5' UTRs include a disproportionately high
number of proto-oncogene products. Many of these transcripts also
contain IRES elements and are therefore more effectively translated
by cap-independent protein synthesis. In contrast, mRNAs that
encode housekeeping proteins rarely have highly structured 5'
UTRs (Sonenberg, 1994). eIF4E over-expression preferentially
increases the synthesis of a number of oncoproteins. Cyclin D1,
c-Myc, RNR2, ODC, FGF-2, and VEGF are all up-regulated in
conjunction with eIF4E. Most of these factors have complex mRNA
5' UTRs and all have been implicated in malignancy (Rosenwald et
al, 1999; Berkel et al, 2001). It is likely that this is just a small
number of many growth-promoting proteins whose expression is
directly or indirectly regulated by eIF4E. Consequently, a healthy
cell tightly regulates proteins that are necessary in speciﬁc cellular
environments but which could potentially be oncogenic. With an
over-abundance of eIF4E this regulation would be lost.
eIF5A
eIF5A is unique in that it is the only cellular protein so far known
to contain the amino acid hypusine. eIF5A is not required for
general protein synthesis but rather to facilitate the translation of
speciﬁc subsets of mRNAs. It has also been implicated in mRNA
transport and stability (Wang et al, 2001). To date, two human
isoforms of eIF5A have been identiﬁed (eIF5A1 and eIF5A2) and
ampliﬁcation of the eIF5A2 gene has been found in ovarian cancer
(Guan et al, 2001). Depletion of eIF5A in S. cerevisiae causes cell
cycle arrest at G1/S phase suggesting that it speciﬁcally directs
the translation of mRNAs required for cell growth (Wang et al,
2001). It is conceivable that over-expression of equivalent proteins,
caused by excess eIF5A in human cells, could enhance cell growth
and contribute to tumorigenesis.
CONCLUSIONS
Early kinetic analyses suggested that normal quiescent cells requires
an increase in global protein synthesis to enter the cell cycle.
According to this view, an unscheduled increase in general transla-
tion would accelerate cell growth and could lead to unscheduled
cell cycle entry. Misregulation of translation factors could therefore
contribute to tumorigenesis simply via induction of superﬂuous
protein synthesis. Alternatively, more subtle alterations in transla-
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the involvement of translation factors in tumorigenesis. Given the
complexity of cancer biology, a more realistic view might involve
a combination of both of these mechanisms.
eIF4E over-expression is consistently found in a wide range of
human tumours (Table 2) and is sufﬁcient to cause malignant
transformation in experimental models. Likewise, surplus eIF2a
may exceed the phosphorylation capacity of eIF2a kinases and
allow ternary complex formation, despite negative regulation.
eIF4G and eIF3 have the potential to bind directly to mRNA, hence
allowing additional translation from IRESs. Overexpression of
eIF4A could increase the unwinding of mRNAs with highly struc-
tured 5' UTRs and allow more efﬁcient translation of these
transcripts. In each case an element of translational control would
be lost.
If misregulation of translation initiation is a common feature of
tumorigenesis, might this generality lead to the identiﬁcation of
new drug targets? Certainly, a variety of agents that inhibit transla-
tion initiation have anticancer activity in experimental models.
Eicosapentaenoic acid (EPA), clotrimazole and thiazolidinediones
inhibit the growth of several cancer cell lines and can also reduce
tumour growth in vivo. All act by releasing Ca
2+ ions from intra-
cellular stores and in this manner stimulate PKR. Hence,
translation is inhibited by phosphorylation of eIF2a and cells are
arrested in G0 (Palakurthi et al, 2000, 2001). Flavonoids, such as
quercetin and genistein, activate all three eIF2a kinases (PKR,
HRI and PERK) and can arrest the growth of leukaemia cells in
vitro (Ito et al, 1999). Rapamycin and rapamycin analogues inhibit
proliferation in a variety of tumour cell lines (Hidalgo and Rowins-
ky, 2000). Rapamycin acts by blocking the protein kinase activity of
FRAP/mTOR, which is ordinarily responsible for phosphorylating
4E-BP1. With 4E-BP1 phosphorylation inhibited, eIF4E is not
released and cap-dependent translation is repressed. Although these
compounds have promising anticancer activities, from a theoretical
standpoint it is not clear why they might have general tumour cell
selectivity; inhibition of translation would be predicted to result in
broadly non-speciﬁc toxicity. Nonetheless, future developments in
this area promise not only to illuminate basic cancer biology but
also to offer exciting new therapeutic tools.
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